Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in advanced hepatocellular carcinoma
NCT01908426Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Sep 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Exelixis, Inc.. Started Sep 2013; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01908426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01908426.